Abstract
Low-grade gliomas are slower growing than their high-grade counterparts. They account for 10–20 % of all primary brain tumors. Median survival is between 4.7 and 9.8 years. The goal of treatment is to prolong overall survival while maintaining good quality of life (QOL). Recent data favors early surgical resection. EOR is associated with delayed tumor recurrence and improved survival. Additional therapy with chemotherapy or radiation is indicated in patients with high-risk features. Lower doses (between 45 and 50.4 Gy) have been shown to be as effective without adverse effects compared to higher doses. Recent trials have shown benefit in combining chemotherapy with radiation compared to radiation alone. The optimal chemotherapeutic regimen (PCV or temozolomide (TMZ)) remains unknown, although TMZ is easier to administer and better tolerated by patients. Novel molecular markers including 1p/19q chromosomal codeletion and isocitrate dehydrogenase 1 (IDH1) mutation have been correlated with treatment response and survival.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4
Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res: Official J Am Assoc Cancer Res 15(1):330–337. doi:10.1158/1078-0432.CCR-08-0888
Turkoglu E, Gurer B, Sanli AM, Dolgun H, Gurses L, Oral NA, Donmez T, Sekerci Z (2013) Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute. Clin Neurol Neurosurg 115(12):2508–2513. doi:10.1016/j.clineuro.2013.10.010
McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J (1992) Treatment and survival of low-grade astrocytoma in adults–1977–1988. Neurosurgery 31(4):636–642 discussion 642
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) European organization for R, treatment of cancer brain tumor cooperative G, European organization for R, treatment of cancer radiotherapy cooperative G. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol: Official J Am Soc Clin Oncol 20(8):2076–2084
Gorlia T, Wu W, Wang M, Baumert BG, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den Bent MJ (2013) New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro-oncology 15(11):1568–1579. doi:10.1093/neuonc/not117
Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109(5):817–824. doi:10.3171/JNS/2008/109/11/0817
Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M, German Glioma N (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res: Official J Am Assoc Cancer Res 17(13):4588–4599. doi:10.1158/1078-0432.CCR-10-3194
Baumert BG, Stupp R. European organization for R, treatment of cancer radiation oncology G, European organization for R, treatment of cancer brain tumor G (2008). Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Ann Oncol: Official J Eur Soc Med Oncol/ESMO 19(Suppl 7):vii217–222. doi:10.1093/annonc/mdn434
Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836. doi:10.1212/01.wnl.0000262034.26310.a2
Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, Solheim O (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, J Am Med Assoc 308(18):1881–1888. doi:10.1001/jama.2012.12807
Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6):1784–1791
Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31(4):431–436. doi:10.1002/ana.410310413
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol: Official J Am Soc Clin Oncol 26(8):1338–1345. doi:10.1200/JCO.2007.13.9337
Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109(5):835–841. doi:10.3171/JNS/2008/109/11/0835
Duffau H (2011) Update on surgery for diffuse low-grade gliomas: brain mapping, hodotopy and neuroplasticity. Bulletin de l’Academie nationale de medecine 195(1):37–49 (discussion 49–51)
van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB, Radiotherapy E, Brain Tumor G, the UKMRC (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 (9490):985–990. doi:10.1016/S0140-6736(05)67070-5
Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36(3):549–556
Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 34(12):1902–1909
Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol: Official J Am Soc Clin Oncol 20(9):2267–2276
Hauswald H, Rieken S, Ecker S, Kessel KA, Herfarth K, Debus J, Combs SE (2012) First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiat Oncol 7:189. doi:10.1186/1748-717X-7-189
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E (2005) Mirimanoff RO, European organisation for R, treatment of cancer brain T, radiotherapy G, national cancer institute of Canada clinical trials G.radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldan GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncol 13(6):649–659. doi:10.1093/neuonc/nor040
Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol: Official J Am Soc Clin Oncol 30(25):3065–3070. doi:10.1200/JCO.2011.35.8598
RTOG 9802: A phase II study of observation in favorable low-grade glioma and a phase III study of radiation with or without PCV chemotherapy in unfavorable low-grade glioma (2014). http://wwwcancergov/newscenter/newsfromnci/2014/RTOG9802v
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol: Official J Am Soc Clin Oncol 31(3):337–343. doi:10.1200/JCO.2012.43.2674
Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol: Official J Am Soc Clin Oncol 22(15):3133–3138. doi:10.1200/JCO.2004.10.169
Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol: Official J Eur Soc Med Oncol/ESMO 14(12):1722–1726
Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103(4):802–809. doi:10.1002/cncr.20828
Fisher BJ LJ, MacDonald DR, Lesser GJ, et al. (2013) A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. J Clin Oncol 31 (suppl; abstr 2008)
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol: Official J Am Soc Clin Oncol 21(4):646–651
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331
Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60(6):740–743. doi:10.1002/ana.21044
Viaccoz A, Lekoubou A, Ducray F (2012) Chemotherapy in low-grade gliomas. Curr Opin Oncol 24(6):694–701. doi:10.1097/CCO.0b013e328357f503
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol: Official J Am Soc Clin Oncol 31(32):4085–4091. doi:10.1200/JCO.2013.49.6968
Baumert B SR Radiation Therapy or temozolomide in treating patients with gliomas (NCT00182819)
KA J Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma (NCT00887146)
Chang S PM Phase II trial of RAD001 in patients with recurrent low grade glioma (NCT00823459)
Prins R Vaccine for patients with newly diagnosed or recurrent low-grade glioma (NCT01635283)
Lustig R Proton beam radiation therapy in treating patients with low grade gliomas (NCT01024907)
Ongoing studies Ref: http://www.clinicaltrials.gov/ct2/results?term=low+grade+glioma&pg=3
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kumthekar, P., Raizer, J., Singh, S. (2015). Low-Grade Glioma. In: Raizer, J., Parsa, A. (eds) Current Understanding and Treatment of Gliomas. Cancer Treatment and Research, vol 163. Springer, Cham. https://doi.org/10.1007/978-3-319-12048-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-12048-5_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12047-8
Online ISBN: 978-3-319-12048-5
eBook Packages: MedicineMedicine (R0)